Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, RxSight Inc’s stock clocked out at $61.42, up 1.25% from its previous closing price of $60.66. In other words, the price has increased by $1.25 from its previous closing price. On the day, 1.83 million shares were traded. RXST stock price reached its highest trading level at $63.2799 during the session, while it also had its lowest trading level at $57.11.
Ratios:
To gain a deeper understanding of RXST’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.18 and its Current Ratio is at 9.20. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on May 07, 2024, Reiterated its Buy rating but revised its target price to $72 from $61 previously.
On December 13, 2023, Wells Fargo Upgraded its rating to Overweight which previously was Equal Weight and also upped its target price recommendation from $31 to $42.
On December 12, 2023, Stifel started tracking the stock assigning a Buy rating and target price of $40.Stifel initiated its Buy rating on December 12, 2023, with a $40 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 03 ’24 when Kurtz Ronald M MD sold 40,000 shares for $60.15 per share. The transaction valued at 2,405,872 led to the insider holds 764,610 shares of the business.
Thunen Shelley B sold 10,000 shares of RXST for $526,913 on May 01 ’24. The Chief Financial Officer now owns 13,938 shares after completing the transaction at $52.69 per share. On Apr 01 ’24, another insider, Thunen Shelley B, who serves as the Chief Financial Officer of the company, sold 20,000 shares for $49.90 each. As a result, the insider received 997,946 and left with 8,402 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXST now has a Market Capitalization of 2284596736 and an Enterprise Value of 2133497984. For the stock, the TTM Price-to-Sale (P/S) ratio is 22.60 while its Price-to-Book (P/B) ratio in mrq is 13.92. Its current Enterprise Value per Revenue stands at 21.103 whereas that against EBITDA is -49.136.
Stock Price History:
The Beta on a monthly basis for RXST is 1.23, which has changed by 1.7610378 over the last 52 weeks, in comparison to a change of 0.25590587 over the same period for the S&P500. Over the past 52 weeks, RXST has reached a high of $66.54, while it has fallen to a 52-week low of $18.72. The 50-Day Moving Average of the stock is 15.60%, while the 200-Day Moving Average is calculated to be 57.70%.
Shares Statistics:
It appears that RXST traded 419.34K shares on average per day over the past three months and 483810 shares per day over the past ten days. A total of 36.14M shares are outstanding, with a floating share count of 31.30M. Insiders hold about 15.85% of the company’s shares, while institutions hold 79.07% stake in the company. Shares short for RXST as of 1713139200 were 1467792 with a Short Ratio of 3.50, compared to 1710460800 on 1295125. Therefore, it implies a Short% of Shares Outstanding of 1467792 and a Short% of Float of 4.16.
Earnings Estimates
Investors are keenly observing as 7.0 analysts analyze and rate the current performance of RxSight Inc (RXST) in the stock market.On average, analysts expect EPS of -$0.21 for the current quarter, with a high estimate of -$0.08 and a low estimate of -$0.26, while EPS last year was -$0.4. The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.09 and low estimates of -$0.25.
Analysts are recommending an EPS of between -$0.33 and -$0.91 for the fiscal current year, implying an average EPS of -$0.77. EPS for the following year is -$0.55, with 6.0 analysts recommending between -$0.36 and -$0.74.
Revenue Estimates
In the current quarter, 6 analysts expect revenue to total $32.28M. It ranges from a high estimate of $32.6M to a low estimate of $32M. As of the current estimate, RxSight Inc’s year-ago sales were $20.81MFor the next quarter, 6 analysts are estimating revenue of $33.12M. There is a high estimate of $33.8M for the next quarter, whereas the lowest estimate is $32.8M.
A total of 7 analysts have provided revenue estimates for RXST’s current fiscal year. The highest revenue estimate was $135.7M, while the lowest revenue estimate was $130.8M, resulting in an average revenue estimate of $134.36M. In the same quarter a year ago, actual revenue was $89.08MBased on 7 analysts’ estimates, the company’s revenue will be $179.96M in the next fiscal year. The high estimate is $192.83M and the low estimate is $168M.
